Effects of Alagebrium, an Advanced Glycation Endproduct Breaker, on Exercise Tolerance and Cardiac Function in Patients with Chronic Heart Failure
Why the study?
Does alagebrium improve exercise tolerance in patients with chronic heart failure and LVEF ≤0.45?
Population
102 patients with chronic heart failure and left ventricular ejection fraction ≤0.45, mean age 62 ± 11…
Comparison
Alagebrium 200 mg twice daily for 36 weeks vs Placebo
Design
RCT, randomized, double-blind
Follow-up
36 weeks
Authors
Discussion
Loading...
Member takes
Implication
Alagebrium does not improve exercise tolerance in systolic HF; challenges prior preliminary data and does not support further development.
Structured PICO
Does alagebrium improve exercise tolerance in patients with chronic heart failure and LVEF ≤0.45?
P
Population
102 patients with chronic heart failure and left ventricular ejection fraction (LVEF) ≤0.45, mean age 62 ± 11 years, 78% male.
I
Intervention
Alagebrium 200 mg twice daily for 36 weeks
C
Comparator
Placebo
O
Outcome
Change in peak VO2 at 36 weekssurrogate
The AGE-breaker alagebrium did not improve exercise tolerance or cardiac function in patients with systolic heart failure, failing to support earlier preliminary data.
Cite This Study
Hartog et al. (2011) studied this question.